Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM) Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, W., Smith, M., Frank, M., Miklos, D., Dahiya, S., Hosoya, H., Mikkilineni, L., Sidana, S. ELSEVIER. 2025: 4586-4587View details for DOI 10.1182/blood-2025-4586
View details for Web of Science ID 001664496300036